In 2010, around 130 brands like Zoloft and Lipitor constituted for 34% of the universal pharma sector sales. Following the same year, many other drug companies hewed from the permit. The sector has changed in countless ways.
The questionnaire raised queries on the basis of key parameters like empathy for healthcare providers, quality content and motivation for patients. However, qualities like credible scientific content and values not related to promotional activities emerged as strong criterion for building trust.
On Monday Takeda Pharmaceutical confirmed to acquire Shire for £45.3 billion ($61.50 billion). The final deal will be 46 percent cash and 54 percent stock.
Consumers are depending on mHealth applications and wearable devices to improve their medication abidance.
During the Fitbit Q1 earnings call, the company confirmed its focus on digital health regardless of the expected decline in sales numbers. Currently, Fitbit is focusing on its new alliance with Google, wherein the two companies will work together to speed up innovation in the digital health space to provide clear EHRs and precise patient data to help the clinicians.
In a bid to sweeten its deal for Fortis Healthcare, Manipal Health Enterprises has proposed merging of both enterprises that pegs the value of the beleaguered Fortis at Rs. 8,358 crores. The buyout efforts of Manipal have been backed by US private equity firm TPG.
Suki, a California-based, health-tech startup founded by former Flipkart executive in 2017 is said to have raised a new round of capital of $15 million.
Lately, Biotech and immunotherapy have been widely covered by media, but there’s more to healthcare than taking leaps of faith on new tech. New companies are addressing administrative functions, personalized medicine, and proactive wellness in their approach to the health industry.
Recode project will use Cellectis’ TALEN gene editing technology to create first virus-resistant human cells for manufacturing therapeutics and developing new cell-based therapies
Gilead Sciences (NSDQ:GILD) is reportedly slated to pay Alphabet’s Verily Life Sciences $90 million over three years to analyze cells from patients with rheumatoid arthritis, inflammatory bowel disease and lupus-related diseases.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.